RTS,S/AS01E fractional 加强针在控制性疟疾感染中效果的 IIA 期延伸研究
该延伸研究纳入 49 名既往接受过 RTS,S/AS01 延迟分次剂量方案并完成控制性人类疟疾感染(CHMI)的受试者,在初免后 12 个月给予 1/5 剂量容积的 RTS,S/AS01E 加强针,3 周后再次 CHMI。总体再攻击疫苗效力为 53%(95%CI:37-65%),既往保护者与非保护者相似;加强针耐受良好。
要点
- fractional RTS,S/AS01E 加强针在初免后 12 个月可延长或诱导对 CHMI 的保护。
- 再攻击总体疫苗效力 53%(95%CI:37-65%),不受初免方案或既往保护状态影响。
- 再攻击后的保护与更高的抗 CS 抗体应答相关。
核心结论
- 初免两剂或三剂 RTS,S/AS01 延迟分次剂量方案完成一年后,给予 fractional RTS,S/AS01E 加强针可延长或诱导对 CHMI 的保护。
研究设计与样本
- IIA 期延伸试验,49 名受试者(既往保护者 25 名,非保护者 24 名)在初免后 12 个月接受 1/5 剂量容积 RTS,S/AS01E 加强针,3 周后行恶性疟原虫 CHMI,随后随访 6 个月评估安全性和免疫原性。
主要发现
- 再攻击总体疫苗效力为 53%(95%CI:37-65%),既往保护者为 52%(95%CI:28-68%),非保护者为 54%(95%CI:29-70%)。
- 加强接种后抗 CS(重复区)抗体几何平均浓度(GMC)升高。
- 初免三剂组 GMC 随时间维持,而两剂组下降。
- 再攻击后的保护与更高的抗 CS 抗体应答相关。
- 加强针耐受良好。
临床怎么用
- 对于完成两剂或三剂 RTS,S/AS01 延迟分次剂量初免方案者,可考虑在 12 个月时给予 fractional RTS,S/AS01E 加强针以延长或诱导保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously demonstrated that RTS,S/AS01B and RTS,S/AS01E vaccination regimens including at least one delayed fractional dose can protect against Plasmodium falciparum malaria in a controlled human malaria infection (CHMI) model, and showed inferiority of a two-dose versus three-dose regimen. In this follow-on trial, we evaluated whether fractional booster vaccination extended or induced protection in previously protected (P-Fx) or non-protected (NP-Fx) participants. METHODS: 49 participants (P-Fx: 25; NP-Fx: 24) received a fractional (1/5th dose-volume) RTS,S/AS01E booster 12 months post-primary regimen. They underwent P. falciparum CHMI three weeks later and were then followed for six months for safety and immunogenicity. RESULTS: Overall vaccine efficacy against re-challenge was 53% (95% CI: 37-65%), and similar for P-Fx (52% [95% CI: 28-68%]) and NP-Fx (54% [95% CI: 29-70%]). Efficacy appeared unaffected by primary regimen or previous protection status. Anti-CS (repeat region) antibody geometric mean concentrations (GMCs) increased post-booster vaccination. GMCs were maintained over time in primary three-dose groups but declined in the two-dose group. Protection after re-challenge was associated with higher anti-CS antibody responses. The booster was well-tolerated. CONCLUSIONS: A fractional RTS,S/AS01E booster given one year after completion of a primary two- or three-dose RTS,S/AS01 delayed fractional dose regimen can extend or induce protection against CHMI. CLINICAL TRIAL REGISTRATION: NCT03824236. linked to this article can be found on the Research Data as well as Figshare https://figshare.com/s/ee025150f9d1ac739361.
引用
- Moon JE, Greenleaf ME, Regules JA, et al. A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge. Vaccine. 2021. PMID: 34593270. doi:10.1016/j.vaccine.2021.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。